Ignite Creation Date:
2024-05-06 @ 10:20 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03232073
Status:
COMPLETED
Last Update Posted:
2024-02-02
First Post:
2017-07-20
Brief Title:
Long-term Extension to Study AC-058B301 to Investigate Safety Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Multicenter Non-comparative Extension of Study AC-058B301 to Investigate the Long-term Safety Tolerability and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMUM-LT
Brief Summary:
The study AC-058B301 OPTIMUM NCT02425644 has been designed to investigate the efficacy safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis RMS The AC-058B303 study is the long-term extension for the core study AC-058B301 The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety tolerability and control of disease of ponesimod 20 mg in subjects with RMS
Detailed Description:
The AC-058B303 study extension study is the long-term extension for the AC-058B301 study core study The core study has been designed to investigate the efficacy safety and tolerability of ponesimod in subjects with RMS The subjects are treated with either ponesimod or the active comparator teriflunomide in the core study The purpose of this long term extension of the core study is to characterize the long-term safety and control of disease of ponesimod in subjects with RMS In particular the study will allow to observe potential adverse events which may only occur after long term treatment with ponesimod The study will also investigate the effect of re-initiation of ponesimod after a brief interruption in a relatively large population all subjects treated with ponesimod in the core study and eligible for the extension study on disease activity in terms of relapses and MS-related MRI lesions There is currently limited guidance on when a new MS treatment should be started after discontinuation of teriflunomide and the study will contribute with data on safety and efficacy of switching from teriflunomide to ponesimod after an interruption as mandated by the protocol The study will also allow confirmation of sustained efficacy of ponesimod in terms of relapses MRI lesions and reduction of disability accumulation during long-term treatment In addition combined data from the core study together with the results of the current extension study will allow comparison of MS activity in subjects who were switched from teriflunomide to ponesimod versus those who were treated with ponesimod in both studies A vaccination sub-study will be conducted in a sub-set of up to 50 eligible study participants from selected countries who consent to be vaccinated with the Janssen coronavirus disease-2019 COVID-19 vaccine Ad26COV2S to investigate the immune response induced by the Janssen COVID-19 vaccine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-004719-10 | EUDRACT_NUMBER | None | None |